Food, Drugs, Healthcare, Life Sciences

The UK's medicines regulator is proposing fundamental changes to how gene therapy products are defined, shifting from origin-based classifications to mechanism-driven frameworks. This consultation raises critical questions about where regulatory boundaries will be drawn for synthetic biology, genome editing platforms, and engineered cell therapies as biotechnology advances beyond traditional biological manufacturing.

The phrase "clinically proven" is one of the most powerful claims in a beauty marketer's ‘Arsenal’*. It sounds scientific, authoritative, and reassuring. But in a ruling published in April 2026,...

The MHRA’s proposed rare disease therapies regulatory framework (“the Proposed Framework”) represents an ambitious attempt to redesign medicines regulation around the realities of rare disease development.

The phrase "clinically proven" is one of the most powerful claims in a beauty marketer's ‘Arsenal’*. It sounds scientific, authoritative, and reassuring. But in a ruling published in April 2026,...

Launching a product while a patent dispute remains unresolved has never been risk‑free, but many companies have taken the view that the commercial upside justified it.

The MHRA’s proposed rare disease therapies regulatory framework (“the Proposed Framework”) represents an ambitious attempt to redesign medicines regulation around the realities of rare disease development.

The UK's medicines regulator is proposing fundamental changes to how gene therapy products are defined, shifting from origin-based classifications to mechanism-driven frameworks. This consultation raises critical questions about where regulatory boundaries will be drawn for synthetic biology, genome editing platforms, and engineered cell therapies as biotechnology advances beyond traditional biological manufacturing.

Artificial intelligence is transforming how pharmaceutical companies identify new therapeutic uses for existing drugs, but this acceleration creates complex intellectual property challenges. As computational methods rapidly generate repurposing candidates, innovators must navigate the tension between filing early to secure priority and waiting for sufficient validation data, while ensuring their second medical use patents provide meaningful commercial protection in an increasingly competitive landscape.

Launching a product while a patent dispute remains unresolved has never been risk‑free, but many companies have taken the view that the commercial upside justified it.